Bateman’s laboratory focuses on the causes, diagnosis and future treatments of Alzheimer’s disease (AD). We directly measure the pathology and pathophysiology of AD in humans using multiple techniques. Our group uses a wide variety of assays and techniques from the most basic applications, such as quantitative measurement of stable-isotope labeled peptides, to clinical translational studies in diagnostic and therapeutic biomarkers for AD.
The Bateman lab is currently looking for additional team members and has several exciting opportunities for qualified motivated candidates!
Randall J. Bateman, MD
Randall J. Bateman, MD, is the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine, director of the Dominantly Inherited Alzheimer Network (DIAN) and director of the DIAN Trials Unit (DIAN-TU).
Bateman’s laboratory investigates the causes and methods of diagnosis and treatment of Alzheimer’s disease (AD) utilizing a wide variety of assays and techniques from…
New center’s aim: to ID biomarkers of neurodegenerative diseases (Links to an external site)
Blood test for Alzheimer’s highly accurate in large, international study (Links to an external site)
Donate to the Bateman Alzheimer’s research fund.